Results 121 to 130 of about 5,544 (172)

Urate-lowering therapy is associated with a reduced risk of arrhythmias: a systematic review and meta-analysis. [PDF]

J Rheum Dis
Waitayangkoon P, Leesutipornchai T, Techasatian W, Aiumtrakul N, Tanariyakul M, Arayangkool C, Kanthajan T, Nagamine T, Kewcharoen J.   +8 more
europepmc   +1 more source

Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. [PDF]

Arthritis Rheumatol
Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Wu H, Kramer B, Mikuls TR.   +13 more
europepmc   +1 more source

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. [PDF]

Arthritis Res Ther
Holladay EE, Mudano AS, Xie F, Zhang J, Mikuls TR, LaMoreaux B, Padnick-Silver L, Curtis JR.   +7 more
europepmc   +1 more source

Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. [PDF]

Ann Rheum Dis
Tedeschi SK, Hayashi K, Zhang Y, Choi H, Solomon DH.   +4 more
europepmc   +1 more source

Erratum: Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study [Corrigendum]. [PDF]

J Inflamm Res
europepmc   +1 more source

Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]

Rheumatology (Oxford)
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution

Seminars in Arthritis and Rheumatism, 2017
The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, and in some countries it is already recommended.
Lisa K Stamp, Nicola Dalbeth
exaly   +4 more sources

Urate-lowering therapy agents

2016
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
exaly   +2 more sources